Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.

AV1451 precursor

  Cat. No.:  DC67414  
Chemical Structure
1533432-50-6
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
Cas No.: 1533432-50-6
Chemical Name: Tert-Butyl 7-(6-nitropyridin-3-yl)-5H-pyrido[4,3-b]indole-5-carboxylate
Synonyms: tert-Butyl 7-(6-nitropyridin-3-yl)-5H-pyrido[4,3-b]indole-5-carboxylate;C1=C2N(C(=O)OC(C)(C)C)C3=CC=NC=C3C2=CC=C1C1=CC=C([N+]([O-])=O)N=C1;WS-00914;WS-00914;5-Boc-7-(6-nitro-3-pyridyl)-5H-pyrido[4,3-b]indole;5-Boc-7-(6-nitro-3-pyridyl)-5H-pyrido[4,3-b]indole;SCHEMBL16268180;SCHEMBL16268180;tert-Butyl7-(6-nitropyridin-3-yl)-5H-pyrido[4,3-b]indole-5-carboxylate;tert-Butyl7-(6-nitropyridin-3-yl)-5H-pyrido[4,3-b]indole-5-carboxylate;SY130921;SY130921;tert-butyl 7-(6-nitropyridin-3-yl)pyrido[4,3-b]indole-5-carboxylate;tert-butyl 7-(6-nitropyridin-3-yl)pyrido[4,3-b]indole-5-carboxylate;E71391;E71391;1533432-50-6;1533432-50-6
SMILES: O(C(N1C2C=CN=CC=2C2C=CC(C3C=NC(=CC=3)[N+](=O)[O-])=CC1=2)=O)C(C)(C)C
Formula: C21H18N4O4
M.Wt: 390.4
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
MSDS
Cat. No. Product name Field of application
DC67548 NOP-1A NOP-1A standard. 11C-NOP-1A is a new radioligand for thenociceptin/orphanin FQ peptide (NOP) receptor, with high affinity (Ki, 0.15 nM) and appropriate lipophilicity (measured logD, 3.4) for PET brain imaging. 11C-NOP-1A is the the first successful radioligand to image NOP receptors in rat and monkey brain. 11C-NOP-1A is a selective antagonist at the NOP receptor and has high affinity and appropriate lipophilicity for blood–brain barrier permeability. 11C-NOP-1A imaging in rhesus monkeys showed high brain uptake and a large receptor-specific signal and could be quantified with the gold standard method of compartmental modeling. In humans 1C-NOP-1A reliably quantified NOP receptors in human brain both in large brain regions and at a voxelwise level using parametric imaging. The radiation absorbed dose in humans was similar to that observed with other 11C-labeled ligands and would allow multiple scans of a single subject. Thus, 11C-NOP-1A is a promising radioligand for reliably quantifying NOP receptors in human brain.
DC67547 NOP-1A Precursor The Precursor of NOP-1A.  (11)C-NOP-1A is a useful radioligand for quantifying NOP receptors in the monkey brain, and its radiation dose is similar to that of other (11)C-labeled ligands for neuroreceptors.
DC67437 PI-2620 precursor PI-2620 precursor is the precursor of PI2620. 18F-PI-2620 is a PET tracer with high binding affinity for aggregated tau, a key pathologic feature of Alzheimer disease (AD) and other neurodegenerative disorders.
DC60818 mono-Boc-Br MK-6240 Precursor mono-Boc-Br MK-6240 Precursor is the precusor of MK-6240.. (18)F]-MK-6240 is a tau positron emission tomography (PET) tracer for neurofibrillary tangles (NFTs), exhibiting high specificity and selectivity for binding to NFTs .
DC67414 AV1451 precursor
DC67285 DOTA-Octreotide
DC67284 NOTA-NOC
DC60791 Cholestify Precursor Precursor of Cholestify,18F-Cholestify, which binds cytochrome P450 46A1, detected cholesterol breakdown in the mammalian brain. CYP46A1 converts cholesterol to 24-hydroxycholesterol, a form easily eliminated from the brain.
DC60790 DesMEM AZD4694 DesMEM AZD4694(AZD4694 Precursor 1)is the precursor of [18F] AZD4694 for the synthesis of [18F] AZD4694, an amyloid-β imaging ligand with high affinity for amyloid-β plaques.
DC66469 DOTA-NOC DOTA-NOC (DOTA-Nal3-octreotide) is a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5. DOTA-NOC can be used for labeling with various radiometals, and development of radiopeptide imaging.
X